





CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
S.K. Tower, Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

PATIENT NAME	: GANESH SRIRA	NG	PATIENT ID : GANEM300885181
ACCESSION NO :	0181WA00113	AGE : 37 Years SEX : Male	ABHA NO :
DRAWN :		RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53
REFERRING DOCTOR: SELF CLIENT PATIENT ID :			


Test Report Status Final Results Biological Reference Interval Units
--

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	15.1		13.0 - 17.0	g/dL
METHOD : SLS- HEMOGLOBIN DETECTION METHOD				
RED BLOOD CELL (RBC) COUNT	5.11		4.5 - 5.5	mil/µL
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION				
WHITE BLOOD CELL (WBC) COUNT	10.52	High	4.0 - 10.0	thou/µL
METHOD : FLUORESCENCE FLOW CYTOMETRY				
PLATELET COUNT	289		150 - 410	thou/µL
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	48.4		40.0 - 50.0	%
METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD				
MEAN CORPUSCULAR VOLUME (MCV)	94.7		83.0 - 101.0	fL
METHOD : CALCULATED FROM RBC & HCT				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.5		27.0 - 32.0	pg
METHOD : CALCULATED FROM THE RBC & HGB				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED FROM THE HGB & HCT	31.2	Low	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	12.5		11.6 - 14.0	%
METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE				
MENTZER INDEX	18.5			
MEAN PLATELET VOLUME (MPV)	9.9		6.8 - 10.9	fL
METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATO	CRIT			
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	53		40 - 80	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
LYMPHOCYTES	37		20 - 40	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
MONOCYTES	6		2 - 10	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
EOSINOPHILS	3		1 - 6	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
BASOPHILS	1		0 - 1	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE NEUTROPHIL COUNT	5.53		2.0 - 7.0	thou/µL







Patient Ref. No. 775000002220826

LIPID PROFILE, SERUM

DIAGNOSTIC REPORT











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

CLIENT PATIENT ID:

PATIENT NAME	: GANESH SRIRA	NG	PATIENT ID : GANEM300885181
ACCESSION NO :	0181WA00113	AGE : 37 Years SEX : Male	ABHA NO :
DRAWN :		RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53

REFERRING DOCTOR : SELF

ſ

Test Report Status <u>Final</u>	Results		Biological Reference Interval Units	
CHOLESTEROL, TOTAL	260	High	Desirable cholesterol level mg/dL < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	
METHOD : ENZYMATIC COLORIMETRIC ASSAY	149		Normal: < 150 mg/dL Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	
METHOD : ENZYMATIC COLORIMETRIC ASSAY			, , , , , , , , , , , , , , , , , , , ,	
HDL CHOLESTEROL	51		Low HDL Cholesterol <40 mg/dL	
METHOD : ENZYMATIC, COLORIMETRIC			High HDL Cholesterol >/= 60	
CHOLESTEROL LDL	179	High	Adult levels: mg/dL Optimal < 100 Near optimal/above optimal: 100- 129 Borderline high : 130-159 High : 160-189 Very high : = 190	
METHOD : ENZYMATIC COLORIMETRIC ASSAY				
NON HDL CHOLESTEROL	209	High	Desirable : < 130 mg/dL Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	
VERY LOW DENSITY LIPOPROTEIN	29.8		< OR = 30.0 mg/dL	
CHOL/HDL RATIO	5.1	High	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0	
LDL/HDL RATIO	3.5	High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
DRAWN :	RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53
ACCESSION NO : 0181WA00113	AGE : 37 Years SEX : Male	ABHA NO :
PATIENT NAME : GANESH SRIRA	NG	PATIENT ID : GANEM300885181

Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.

2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction.Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category				
Extreme risk group	A.CAD with > 1 feature of high risk group			
	B. CAD with > 1 feature of Very high risk	group or recurrent ACS (within 1 year) despite LDL-C		
	< or $=$ 50 mg/dl or polyvascular disease			
Very High Risk	1. Established ASCVD 2. Diabetes with 2	major risk factors or evidence of end organ damage 3.		
	Familial Homozygous Hypercholesterolemi	ia		
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end			
	organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6.			
	Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid			
	plaque			
Moderate Risk	2 major ASCVD risk factors			
Low Risk	0-1 major ASCVD risk factors			
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors				
1. Age $>$ or $=$ 45 year	1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females 3. Current Cigarette smoking or tobacco use			
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure			
5. Low HDL				

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy		
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	
Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80	
Category A	< OR = 30)	< OR = 60)			









DIAGNOSTIC REPORT

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA DELHI INDIA 8800465156

PATIENT NAME : GANESH SRIR	ANG	PATIENT ID : GANEM300885181
ACCESSION NO : 0181WA00113	AGE : 37 Years SEX : Male	ABHA NO :
DRAWN :	RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units	

Extreme Risk Group	<or 30<="" =="" th=""><th><or 60<="" =="" th=""><th>> 30</th><th>>60</th></or></th></or>	<or 60<="" =="" th=""><th>> 30</th><th>>60</th></or>	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

,,				
BILIRUBIN, TOTAL	0.43		Upto 1.2	mg/dL
METHOD : COLORIMETRIC DIAZO				
BILIRUBIN, DIRECT	0.23		< 0.30	mg/dL
BILIRUBIN, INDIRECT	0.20		0.1 - 1.0	mg/dL
TOTAL PROTEIN	7.9		6.0 - 8.0	g/dL
METHOD : COLORIMETRIC				
ALBUMIN	5.1	High	3.97 - 4.94	g/dL
METHOD : COLORIMETRIC				
GLOBULIN	2.8		2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.8		1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	56	High	< OR = 50	U/L
METHOD : UV ABSORBANCE				
ALANINE AMINOTRANSFERASE (ALT/SGPT)	111	High	< OR = 50	U/L
METHOD : UV ABSORBANCE				
ALKALINE PHOSPHATASE	64		40 - 129	U/L
METHOD : COLORIMETRIC				
GAMMA GLUTAMYL TRANSFERASE (GGT)	91	High	0 - 60	U/L
METHOD : ENZYMATIC, COLORIMETRIC				
LACTATE DEHYDROGENASE	157		125 - 220	U/L
METHOD : UV ABSORBANCE				
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN	11		6 - 20	mg/dL
METHOD : ENZYMATIC ASSAY				
CREATININE, SERUM				
CREATININE	0.83		0.7 - 1.2	mg/dL
METHOD : COLORIMETRIC				













CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

CLIENT PATIENT ID:

PATIENT NAME : GANESH SRIR	ANG	PATIENT ID : GANEM300885181
ACCESSION NO : 0181WA00113	AGE: 37 Years SEX: Male	ABHA NO :
DRAWN :	RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53

REFERRING DOCTOR : SELF

Test Report Status <u>Final</u>	Results		Biological Reference	Interval Units
BUN/CREAT RATIO	13.25		8.0 - 15.0	
URIC ACID, SERUM				
URIC ACID	7.1	High	3.4 - 7.0	mg/dL
METHOD : ENZYMATIC COLORIMETRIC ASSAY				
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	7.9		6.0 - 8.0	g/dL
METHOD : COLORIMETRIC				
ALBUMIN, SERUM				
ALBUMIN	5.1	High	3.97 - 4.94	g/dL
METHOD : COLORIMETRIC				
GLOBULIN				
GLOBULIN	2.8		2.0 - 3.5	g/dL
ELECTROLYTES (NA/K/CL), SERUM				
SODIUM, SERUM	136		136 - 145	mmol/L
POTASSIUM, SERUM	4.37		3.5 - 5.1	mmol/L
CHLORIDE, SERUM	97	Low	98 - 107	mmol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 9800465156 8800465156

SRL Ltd
S.K. Tower, Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

PATIENT NAME	: GANESH SRIRA	NG	PATIENT ID : GANEM300885181
ACCESSION NO :	0181WA00113	AGE : 37 Years SEX : Male	ABHA NO :
DRAWN :		RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53
REFERRING DOCT	FOR: SELF		CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
PHYSICAL EXAMINA	TION, URINE			
COLOR		PALE YELLOW		
APPEARANCE		CLEAR		
CHEMICAL EXAMINA	TION, URINE			
PH		6.0	5.00 - 7.50	
SPECIFIC GRAVITY		1.020	1.010 - 1.030	
PROTEIN		NOT DETECTED	NOT DETECTED	
GLUCOSE		NOT DETECTED	NOT DETECTED	
KETONES		NOT DETECTED	NOT DETECTED	
BLOOD		NOT DETECTED	NOT DETECTED	
UROBILINOGEN		NORMAL	NORMAL	
NITRITE		NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	E	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAM	INATION, URINE			
RED BLOOD CELLS		NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)		1-2	0-5	/HPF
EPITHELIAL CELLS		1-2	0-5	/HPF
CASTS		NOT DETECTED		
CRYSTALS		NOT DETECTED		
BACTERIA		NOT DETECTED	NOT DETECTED	
YEAST		NOT DETECTED	NOT DETECTED	









DIAGNOSTIC REPORT

CLIENT CODE : C000138394

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA DELHI INDIA 8800465156

SRL Ltd
S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53
ACCESSION NO : 0181WA00113	AGE : 37 Years SEX : Male	ABHA NO :
PATIENT NAME : GANESH SRIRA	NG	PATIENT ID : GANEM300885181

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions		
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any ki		
	of kidney impairment		
Glucose	Diabetes or kidney disease		
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst		
Urobilinogen	Liver disease such as hepatitis or cirrhosis		
Blood	Renal or genital disorders/trauma		
Bilirubin	Liver disease		
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases		
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions		
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time		
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein		
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases		
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice		
Uric acid	arthritis		
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.		
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis		
HYROID PANEL, SERUM			
3	119.0 80 - 200		
- METHOD : ELECTROCHEMILUMINES			

ТЗ	119.0	80 - 200	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE			
T4	8.61	5.1 - 14.1	µg/dL
METHOD : ELECTROCHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	1.58	0.27 - 4.2	µIU/mL
METHOD : ELECTROCHEMILUMINESCENCE			









DIAGNOSTIC REPORT

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53
ACCESSION NO : 0181WA00113	AGE : 37 Years SEX : Male	ABHA NO :
PATIENT NAME : GANESH SRIR	ANG	PATIENT ID : GANEM300885181

CDI 1+d

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions	
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)	
					Post Thyroidectomy (4) Post Radio-Iodine treatment	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid	
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto	
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical	
					inflammation, drugs like amphetamines, Iodine containing drug and	
					dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre	
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid	
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4	
					replacement therapy (7) First trimester of Pregnancy	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent	
					treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED METHOD : VISUAL ABO GROUP & RH TYPE, EDTA WHOLE BLOOD TYPE O ABO GROUP METHOD : GEL COLUMN AGGLUTINATION METHOD. RH TYPE POSITIVE







AGE : 37 Years



CLIENT CODE : C000138394

DIAGNOSTIC REPORT

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA DELHI INDIA 8800465156

PATIENT NAME : GANESH SRIRANG

ACCESSION NO : **0181WA00113**

REFERRING DOCTOR : SELF

Test Report Status

DRAWN :

o

METHOD : GEL COLUMN AGGLUTINATION METHOD.

<u>Final</u>

METHOD : GEL COLUMN AGGLUTINATION METHOD.		
XRAY-CHEST		
IMPRESSION	NO ABNORMALITY DETEC	TED
TMT OR ECHO		
TMT OR ECHO	NEGATIVE	
ECG		
ECG	WITHIN NORMAL LIMITS	
MEDICAL HISTORY		
RELEVANT PRESENT HISTORY	NOT SIGNIFICANT	
RELEVANT PAST HISTORY	H/O CERVICAL SPINE DIS C/O LOW BACK PAIN ON	SC PROLAPSE - TREATED CONSERVATIVELY. & OFF.
RELEVANT PERSONAL HISTORY	MARRIED / MIXED DIET / ALCOHOL.	NO ALLERGIES / 1/DAY- SMOKING / OCC.
RELEVANT FAMILY HISTORY	BOTH PARENTS :- HEART	DISEASE
HISTORY OF MEDICATIONS	CA SUPPLEMENTS	
ANTHROPOMETRIC DATA & BMI		
HEIGHT IN METERS	1.79	mts
WEIGHT IN KGS.	78	Kgs
BMI	24	BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
GENERAL EXAMINATION		
MENTAL / EMOTIONAL STATE	NORMAL	
PHYSICAL ATTITUDE	NORMAL	
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY	
BUILT / SKELETAL FRAMEWORK	AVERAGE	
FACIAL APPEARANCE	NORMAL	
SKIN	NORMAL	
UPPER LIMB	NORMAL	
LOWER LIMB	NORMAL	
NECK	NORMAL	
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TEND	ER
THYROID GLAND	NOT ENLARGED	
CAROTID PULSATION	NORMAL	
TEMPERATURE	NORMAL	











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA

SRL Ltd
S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

DELHI INDIA 8800465156	Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.thane@srl.in		
PATIENT NAME : GANESH SRIRA	NG	PATIENT ID : GANEM300885181	
ACCESSION NO : 0181WA00113	AGE: 37 Years SEX: Male	ABHA NO :	
DRAWN :	RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53	
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:	
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units	
PULSE	92/MIN.REGULAR, ALL BRUIT	PERIPHERAL PULSES WELL FELT, NO CAROTID	
RESPIRATORY RATE	NORMAL		
CARDIOVASCULAR SYSTEM			
BP	120/80 MM HG (SUPINE)	mm/Hg	
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS MURMURS	NORMAL ABSENT		
RESPIRATORY SYSTEM	ABSENT		
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL))	
ADDED SOUNDS	ABSENT		
PER ABDOMEN			
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
HERNIA	ABSENT		
CENTRAL NERVOUS SYSTEM			
HIGHER FUNCTIONS	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
REFLEXES	NORMAL		
MUSCULOSKELETAL SYSTEM			

NORMAL

NORMAL

JOINTS

BASIC EYE EXAMINATION CONJUNCTIVA NORMAL EYELIDS NORMAL



SPINE









CLIENT CODE: C000138394

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

PATIENT NAME: GANESH SRIRANG				NT ID : GANEM300885181
ACCESSION NO :	0181WA00113	AGE : 37 Years SEX : Male	ABHA NO :	
DRAWN :		RECEIVED : 28/01/2023 08:38	REPORTED : 3	1/01/2023 15:53
REFERRING DOCT	OR: SELF		CLIENT PA	ATTENT ID :

Test Report Status <u>Final</u>	Results	Biological Reference Interval	Units
EYE MOVEMENTS	NORMAL		
CORNEA	NORMAL		
DISTANT VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT		
DISTANT VISION LEFT EYE WITHOUT GLASSES	REDUCED VISUAL ACUITY	6/12	
DISTANT VISION RIGHT EYE WITH GLASSES	GLASSES NOT BROUGHT.		
DISTANT VISION LEFT EYE WITH GLASSES	GLASSES NOT BROUGHT.		
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT		
NEAR VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT		
COLOUR VISION	NORMAL		
SUMMARY			
RELEVANT HISTORY	NOT SIGNIFICANT		
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT		
REMARKS / RECOMMENDATIONS	CERVICAL DISC BULGE & OPHTHALMOLOGY CONSU LOW FAT,LOW CALORIE, REGULAR EXERCISE.REG	INE SURGEON FOR LOW BACK PAIN SPONDYLOSIS ILT FOR REDUCED VISUAL ACUITY LOW CARBOHYDRATE, HIGH FIBRE D JLAR WALK FOR 30-40 MIN DAILY. LOOD SUGAR,URIC ACID AFTER 3 M	DIET.

AVOID HIGH QUALITY PROTEIN DIET.

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope. ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION** :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia









DIAGNOSTIC REPORT

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53
ACCESSION NO : 0181WA00113	AGE: 37 Years SEX: Male	ABHA NO :
PATIENT NAME : GANESH SRIR	ANG	PATIENT ID : GANEM300885181

CDLIEd

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical,

stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE:

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and< 40 mg/dL in women. While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1.Evaluating the long-term control of blood glucose concentrations in diabetic patients. 2.Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes). The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for

well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

III.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin. III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection, ischemia to the liver, chronic beautifue of bile ducts circheorie. hepatitis.obstruction of bile ducts.cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget"""'s disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilson"""'s disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULI	
SOUTH WEST DELHI	
NEW DELHI 110030	
DELHI INDIA	
8800465156	

SRL Ltd
S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email : customercare.thane@srl.in

Test Report Status <u>F</u>	inal	Results	Biological Reference	Interval Units
REFERRING DOCTOR : SE	LF		CLIENT PATIENT ID	:
DRAWN :	RECEIVED : 28	/01/2023 08:38	REPORTED : 31/01/20	23 15:53
ACCESSION NO : 0181W	A00113 AGE : 37 Years	SEX : Male	ABHA NO :	
PATIENT NAME : GANE	SH SRIRANG		PATIENT ID :	GANEM300885181

pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom""" disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorbion, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract
Kidney problems, such as kidney damage or failure, infection, or reduced blood flow

Loss of body fluid (dehydration)

Muscle problems, such as breakdown of muscle fibers

• Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

Myasthenia Gravis

Muscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic svndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc. ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface

of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.







8800465156	Email : customercare.thane@srl.in		
PATIENT NAME : GANESH SRIR	ANG	PATIENT ID : GANEM300885181	
ACCESSION NO : 0181WA00113	AGE : 37 Years SEX : Male	ABHA NO :	
DRAWN :	RECEIVED : 28/01/2023 08:38	REPORTED : 31/01/2023 15:53	
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :	

Results

Test Report Status <u>Final</u>

DELHI INDIA

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN **ULTRASOUND ABDOMEN** Grade I fatty liver.

End Of Report Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form. 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services. 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. SRL confirms that all tests have been performed or assayed with highest guality standards, clinical safety & technical integrity.

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

Test results may vary based on time of collection, 7. physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes. 9. In case of gueries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062







Units